The link between chromosomal abnormalities and cancer was first proposed by the German botanist, Theodor Boveri, more than a hundred years ago (Boveri, 1914) . By following cell division in the sea urchin egg, he occasionally observed aberrant mitoses leading to abnormalities in chromosome numbers in the daughter cells, a state otherwise known as aneuploidy. Since then, mounting evidence has linked numerical and structural chromosomal abnormalities to aggressive tumor behavior.
Aneuploidy versus CIN
Prior to engaging in a discussion of chromosomal instability (CIN) and cancer, an important distinction should be drawn between aneuploidy and CIN. The former denotes a state of abnormalor non-euploid-chromosome number, whereas the latter refers to ongoing chromosome segregation errors throughout consecutive cell divisions (Lengauer et al., 1998) . The two often cooccur in human cancer; tumors with high levels of chromosome copy-number abnormalities also exhibit evidence of sustained chromosome missegregation. Yet, stable aneuploidies can exist in the absence of CIN, as is the case with some hematologic malignancies (Paulsson and Johansson, 2007) . This can be due to very low chromosome missegregation rates or strong selective pressure for chromosome copy-number (or karyotype) combinations.
While aneuploidy can be readily assessed using widely available experimental techniques such as bulk DNA sequencing, fluorescence in situ hybridization (FISH), or conventional karyotyping, CIN can only be indirectly inferred using these methods. Experimental evaluation of CIN must identify the ongoing rate of chromosome missegregation. This can be achieved by observing the frequency of cells undergoing anaphase, clonal assays, single-cell sequencing with phylogenetic tree reconstruction, or multi-region tumor sequencing, taking into account allele-specific copy-number information (Bakhoum et al., 2011; Bakker et al., 2016; Jamal-Hanjani et al., 2017; Lengauer et al., 1997) .
CIN and Cancer: A Complex Relationship
It is estimated that 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN (Cimini, 2008; Carter et al., 2012) . CIN positively correlates with tumor stage and is enriched in relapsed as well as metastatic tumor specimens Goh et al., 2017; Turajlic et al., 2018) . Furthermore, complex aneuploidies and polyploidy resulting from whole-genome doubling are features of tumor types with a predilection for metastasis, treatment resistance, and decreased overall survival, such as triple-negative breast cancer, pancreatic and hepatobiliary cancers, lung cancer, anaplastic thyroid cancer, castrate resistant prostate cancer, poorly differentiated sarcomas, gynecologic tumors with serous histologies, glioblastoma, esophagogastric cancers, and microsatellite stable colorectal cancers (Bielski et al., 2018; Carter et al., 2012; Taylor et al., 2018) .
The prevalence of CIN reflects the large number of cancerrelevant pathways whose deregulation has been implicated to influence mitotic chromosome segregation (Thompson et al., 2010a) . Oncogenic signaling, pre-mitotic replication stress, and defects in centrosome replication, sister chromatid cohesion, spindle assembly checkpoint signaling, or microtubule attachments to chromosomes have all been shown to induce CIN. Furthermore, large panoply of anti-neoplastic therapies used in the upfront treatment or metastatic settings can perturb the fidelity of chromosome segregation during anaphase Lee et al., 2016) . Additional prevalent sources of chromosome copy-number alterations in cancer include homologous recombination defects, telomere dysfunction leading to breakage-fusion-bridge cycle (Maciejowski et al., 2015; Yates and Campbell, 2012) . A significant proportion of the defects that induce CIN in cancer converge onto a mitotic phenotype, whereby cells undergoing anaphase exhibit chromosomes that lag in the spindle midzone (Cimini et al., 2001) . These chromosomes are referred to as lagging chromosomes, and they are the result of their erroneous attachments to microtubules at the kinetochores (Figure 1 ). Other signs of chromosome missegregation during mitosis include chromatin bridges, ultrafine DNA bridges, and acentric fragments that fail to establish direct attachments to spindle microtubules. In addition to aneuploidy and large-scale structural chromosomal alterations, chromosome missegregation can lead to focal yet highly complex rearrangements known as chromothripsis, the Multiple defects found in cancer can lead to both numerical and structural chromosomal abnormalities, which often manifest as errors in chromosome segregation during mitosis. These errors lead to aneuploidy and karyotype heterogeneity, as well as the formation of micronuclei. Chromosomes enclosed in micronuclei are subjected to increased DNA damage and can become exposed to the cytosol after micronuclear envelope rupture. This mechanism has been proposed to promote massive structural chromosomal rearrangements, known as chromothripsis, the formation of extrachromosomal DNA as well as double minutes, which can be subjected to strong selective pressures and can be present in hundreds of copies per cell. Furthermore, the presence of cytoplasmic double-stranded DNA (dsDNA) promotes inflammatory signaling through the activation of the cytosolic dsDNA sensing, anti-viral, cGAS-STING pathway.
formation of extrachromosomal DNA and double-minute chromosomes that are amenable to massive copy-number amplifications (Ly et al., 2017; Stephens et al., 2011; Turner et al., 2017; Zhang et al., 2015) (Figure 1 ).
Despite the pervasiveness of CIN in human cancer, its role in tumor evolution is complex and seemingly paradoxical . On one hand, CIN and complex aneuploidies correlate with resistance to antineoplastic agents, such as taxol, both in tumor-derived cell lines as well as in clinical settings (Bakhoum et al., 2011; Carter et al., 2006; Swanton et al., 2009) . Metastatic lesions and circulating tumor cells exhibit evidence for CIN and increased chromosome copy-number heterogeneity Gutenberg et al., 2010; Pailler et al., 2015; Warth et al., 2009) . The presence of chromosome missegregation in primary tumors is associated with a higher likelihood of distant spread, relapse, and oncogene independence in breast and lung cancers, as well as diffuse large B cell lymphoma (DLBCL) (Bakhoum et al., 2011; Sotillo et al., 2010) .
Conversely, excessive levels of CIN forebode enhanced sensitivity to cytotoxic therapies such as cisplatin and 5-Fluorouracil (5-FU) in ovarian, rectal, and breast cancers (Jamal-Hanjani et al., 2015; Roylance et al., 2011; Swanton et al., 2009; Zaki et al., 2014) . Inducing whole-chromosome missegregation sensitizes transplanted human glioblastoma tumors to radiation treatment . This seemingly paradoxical relationship stems from the complexity of the phenotypes imparted by CIN not only on cancer cells, but also on the tumor microenvironment. CIN generates chromosome copy-number heterogeneity that serves as a substrate for natural selection enhancing tumor fitness and facilitating immune evasion, drug resistance, and metastasis (Chen et al., 2012; Davoli et al., 2017; Laughney et al., 2015; Mueller et al., 2018; Notta et al., 2016; Pavelka et al., 2010; Potapova et al., 2013) . In parallel, chromosome segregation errors impart a number of cellular burdens, including loss of genetic material, activation of DNA damage signaling, and induction of proteotoxic stress-all of which can impact viability, particularly in normal or diploid cells (Santaguida et al., 2017; Sheltzer et al., 2017; Torres et al., 2007) (Figure 2 ).
More recently, an intriguing aspect of CIN has been identified whereby chromosome segregation errors as well as replication stress can activate innate immune signaling through the introduction of genomic double-stranded DNA (dsDNA) into the cytosol and engagement of the cGAS-STING cytosolic dsDNAsensing, anti-viral, pathway Coquel et al., 2018; Harding et al., 2017; Mackenzie et al., 2017) . This new dimension adds complexity to our understanding of the role of CIN in tumor evolution. It also reveals that the consequences of CIN are not only tumor-cell autonomous; rather, they are directly involved in the crosstalk between cancer cells and their immune microenvironment. Therefore, to fully appreciate the role of CIN in tumor evolution, it is critical to deconstruct the respective effects of genomic copy-number heterogeneity from those of the transcriptional responses to cytosolic DNA; while they often act in concert to promote therapeutic resistance, immune evasion, and metastasis, in some contexts, they can act in opposite directions (Figure 2 ).
CIN as a Genomic Source for Innate Immune Activation
The link between karyotypic abnormalities and immune activation was first suggested Senovilla et al. upon observing T-lymphocyte-mediated delay in tumor growth in colorectal CT26 tumors that were pharmacologically manipulated to induce aneuploidy (Senovilla et al., 2012) . In this model, enhanced immunogenicity was attributed to increased extracellular calreticulin exposure by cancer cells likely resulting from endoplasmic reticulum stress.
Subsequently, a number of groups have identified a direct mechanism by which chromosome segregation errors can lead to the activation of immune signaling pathways; when chromosomes lag during anaphase, they often form structures termed micronuclei (Crasta et al., 2012; Kato and Sandberg, 1968) . Envelopes surrounding these micronuclei are rupture-prone, leading to exposure of their genomic content to the cytosol (Hatch et al., 2013) (Figure 3 ). When double-stranded DNA Chromosome missegregation influences tumor evolution through the generation of genomic copy-number heterogeneity that serves as the substrate for natural selection. In parallel, ongoing segregation errors can impart a variety of cellular stresses, including transcriptional changes, stemming from the leakage of genomic double-stranded DNA into the cytoplasm, leading to inflammatory signaling. The multi-pronged effects of chromosome segregation enable genomic plasticity and support tumor evolution, facilitating processes such as metastasis, immune evasion, and therapeutic resistance. To fully understand the consequences of CIN, one must first appreciate the diverse effects of chromosome missegregation on the tumor and its microenvironment.
(dsDNA) from micronuclei comes into contact with the cytosol during interphase, it activates the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway Harding et al., 2017; Mackenzie et al., 2017; Yang et al., 2017) . Cytosolic dsDNA is first sensed by cGAS, leading to the catalytic production of the cyclic dinucleotide, cGAMP, which in turn stabilizes STING, promoting its perinuclear localization at the ER membrane (Cai et al., 2014; Ishikawa and Barber, 2008; Ishikawa et al., 2009; Sun et al., 2013) (Figure 3 ). STING mediates the transcriptional activation of inflammatory pathways, including, among others, type I interferon signaling, and the senescence associated-secretory phenotype (SASP). Using fluorescence-activated cell sorting (FACS) followed by singlecell RNA sequencing of RNaseH2 À/À mouse embryonic fibroblasts (MEFs), Mackenzie et al. have elegantly demonstrated that pro-inflammatory interferon-stimulated genes (ISGs) such as CCL5 and CXCL10 are induced exclusively in cells containing micronuclei (Mackenzie et al., 2017) . Subsequently, chromosome-tracking experiments have demonstrated that the same chromosomes that undergo missegregation are the ones that ultimately end up as fragmented cytoplasmic chromatin , providing a direct link between chromosome missegregation and innate immune signaling ( Figure 3 ).
CIN as a Trigger of Tumor Immune Editing
Under normal conditions, the cGAS-STING pathway functions as an innate cellular defense mechanism against viral infections. Once engaged, STING activates TANK-binding kinase 1 (TBK1), promoting the phosphorylation and nuclear translocation of transcription factors such as interferon regulatory factor 3 (IRF3) and nuclear-factor kappa-light-chain-enhancer of activated B cells (NF-kB) (Abe and Barber, 2014) (Figure 3 ). IRF3 and NF-kB mediate the transcription of ISGs and a host of other inflammatory genes, leading to cell death, senescence, and immune-mediated clearance of infected cells (Dou et al., 2017; Galluzzi et al., 2018; Glü ck et al., 2017; Takahashi et al., 2018) . In fact, the accumulation of cytosolic dsDNA, either through endogenous DNA damage or as a result of downregulation of cytoplasmic nucleases such as Trex1, underlies auto-immune conditions such as Aicardi-Goutiè res syndrome and systemic 
CIN Activates cGAS-STING Signaling
Chromosome segregation errors lead to the formation of micronuclei, which often rupture in S phase, exposing double-stranded DNA (dsDNA) to the cytosol. The presence of cytosolic dsDNA activates the anti-viral cGAS-STING pathway, which in normal cells promotes type I interferon production. Chromosomally unstable cancer cells, however, largely suppress type I interferon signaling through multiple mechanisms, yet they maintain the ability to exhibit alternative inflammatory STING-dependent signaling, such as NF-kB. Chronic NF-kB activation has been shown to mediate the senescence-associated secretory phenotype (SASP) as well as cellular migration and distant metastasis.
lupus erythematosus (Crow et al., 2006; Lee-Kirsch et al., 2007; Stetson et al., 2008) . The connection between CIN and the cGAS-STING pathway raises the exciting possibility that chromosome segregation errors could serve as a trigger of immune editing during the early steps of tumorigenesis. Indeed, the generation of complex karyotypes in otherwise diploid retinal pigment epithelial (RPE1) cells activates inflammatory pathways and enhances natural-killer (NK) cell-mediated killing (Santaguida et al., 2017) . Furthermore, inflammatory signaling downstream of cGAS-STING in response to cytoplasmic DNA is a key mechanism in the immune-mediated clearance of cells harboring oncogenic RAS (Dou et al., 2017) . Such a proposition is congruent with the relatively low abundance of chromosome copy-number alterations in early stage tumors, as well as the negative effect of experimentally inducing aneuploidy or chromosome missegregation during early tumorigenesis (Rowald et al., 2016; Sheltzer et al., 2017) .
A potential role for CIN in tumor immune editing is not necessarily at odds with the view that chromosome copy-number heterogeneity enhances the fitness of expanding clones during tumor development once tolerance to aneuploidy and chromosome segregation errors has been established. Indeed, recurrent patterns of chromosome copy-number alterations (CNAs) respond, in part, to metabolic selection pressures and increase the baseline fitness of tumor cells (Graham et al., 2017) . Even in the pre-malignant state, structural and numerical chromosomal alterations help drive early clonal expansions in the peripheral blood (Loh et al., 2018) . Furthermore, a pan-cancer genomic analysis based on the potency and distribution of oncogenes and tumor suppressor genes suggested that cumulative haploinsufficiencies and triplosensitivities drive aneuploidy patterns and shape the cancer genome in primary tumors (Davoli et al., 2013) . Interestingly, these aneuploidies are dependent on the tissue that has given rise to the tumor, and they bolster the underlying genetic network that controls proliferation in a tissue-specific manner (Sack et al., 2018) . These findings might explain tumor type specificity for the observed patterns of chromosome gains and losses such as the amplification of chromosomes 1 and 8 in breast cancer or chromosome 17 loss in ovarian cancer (Goh et al., 2017; Tavassoli et al., 1993) .
In addition to karyotypic changes that enhance fitness through incremental chromosome gains and losses, chromosome missegregation can lead to massive chromosomal rearrangements in the span of a single cell division (Ly et al., 2017; Zhang et al., 2015) . The resulting abnormalities, which include chromothripsis, amplification of double minutes, and extrachromosomal DNA, can be subjected to selective pressures, leading to dramatic changes in copy numbers of individual genomic loci (Stephens et al., 2011; Turner et al., 2017) (Figure 1 ). These punctuated genomic alterations have been proposed to underlie disease progression in pancreatic cancer (Notta et al., 2016) . Collectively, these findings highlight a state of equipoise between the deleterious and beneficial consequences of aneuploidy and CIN during the early steps of tumorigenesis.
Overcoming CIN-Induced Immune Activation
The prevalence of CIN in human cancer indicates that, at some point during tumor evolution, tumor cells grow tolerant to chromosome segregation errors and acquire the ability to evade immune recognition. Experimental evidence suggests that tumors can achieve this tolerance through a number of mechanisms-including adaptively rewiring their response to cytosolic DNA signaling as well as acquiring genomic copy-number heterogeneity-that eschew the deleterious components of innate immune activation. Are cGAS and STING Lost in Chromosomally Unstable Cancer Cells? The immune-stimulatory effect of cGAS-STING activation during viral infection has led to the widespread notion that cGAS and STING are themselves frequently lost in cancer (Konno et al., 2018; Xia et al., 2016a Xia et al., , 2016b . This has been prompted by the observation that a large proportion of cancer cell lines fail to suppress replication-defective oncolytic viruses, a function that is dependent on cGAS-STING activity (Xia et al., 2016a) . Furthermore, cancer cell lines often do not induce ISGs in response to transfection with cGAMP or dsDNA (Lau et al., 2015; Stetson et al., 2008) . However, such defects can result from either the loss of cGAS or STING themselves or a blockade in interferon signaling downstream of STING (Figure 3) .
Pan-cancer genomic data argue against widespread inactivation of cGAS and STING through mutational processes or copynumber alterations. A survey of >10,000 tumors included in the PanCancer TCGA database reveals that genes encoding cGAS and STING are rarely mutated in cancer-with 0.6% and 0.5% of tumors exhibiting mutations in either CGAS or TMEM173, the STING encoding gene, respectively. This is in agreement with Konno et al., who found that <1% of tumors exhibit mutations in these genes and, when experimentally tested, approximately half of these mutations did not impact protein function (Konno et al., 2018) . Furthermore, CGAS and TMEM173 are infrequently altered at the copy-number level, with a larger proportion of tumors exhibiting amplifications rather than deletions (Figure 4 ).
Protein and mRNA expression level data paint a mixed picture. Immunohistochemical analysis in colorectal cancer and melanoma reveals lower cGAS and STING protein levels in advanced stages (Xia et al., 2016a (Xia et al., , 2016b . These losses are also seen in some cancer-derived cell lines and are accompanied by failure to induce type I interferon signaling upon transfection with dsDNA. Similarly, in gastric cancer, reductions in STING mRNA and protein levels correlate with increased tumor stage (Song et al., 2017) , which has led some to propose that loss of these proteins is means for the tumor of escaping immune recognition (Xia et al., 2016b) .
On the other hand, elevated levels of STING protein in tumor cells have been reported in genetically engineered mouse models and patient samples of pancreatic ductal adenocarcinoma (Baird et al., 2016) . Human head-and-neck squamous cell carcinoma tumor cells express higher levels of STING compared to their normal tissue counterpart (Liang et al., 2015) . This is congruent with detectable levels of cGAS and STING proteins in a number of aggressive cancer-derived cell lines such as B16 melanoma, Yac1 lymphoma, multiple myeloma, TRAMP-C2, DU145, PC-3 prostate, head-and-neck squamous cell carcinoma, and MCF-7, 4T1 and MDA-MB-231 breast cancer cells Chandra et al., 2014; Gaston et al., 2016; Ho et al., 2016; Lam et al., 2014; Liang et al., 2015; Takashima et al., 2016; Tang et al., 2016) . Furthermore, many tumors types, including, but not limited to, breast, lung, pancreatic, thyroid, and head-and-neck cancers, exhibit, on average, decreased methylation of the cGAS and STING promoters accompanied by increased mRNA expression levels compared with their normal tissue counterparts (Konno et al., 2018) . Understandably, the promoter methylation status in tumor tissues displays increased variability compared to normal tissues, and a small proportion of tumor samples display hypermethylated promoters. This proportion differed among tumor types, with some, such as colorectal cancer, exhibiting a larger percentage of tumors with hypermethylated promoters, raising the prospects that epigenetic silencing of cGAS-STING signaling might be dependent on the tissue of origin; the colon is an immune-rich environment that imparts unique selective pressures on a nascent tumor. Nonetheless, these data, in sum, suggest that the majority of tumors retain functional copies of cGAS and STING ( Figure 5A ). Tumor Cell-Intrinsic Suppression of Type I Interferon Signaling The presence of cGAS and STING in cancer, however, is not synonymous with induction of type I interferon signaling, which appears to be suppressed to varying degrees in the majority of tumor cell lines despite the presence of cytosolic DNA. An analysis of >1,000 cell lines found in the cancer cell line encyclopedia (CCLE) by Dou et al. has revealed no significant correlation between STING mRNA levels and ISGs (Dou et al., 2017) . Similar results are seen in MDA-MB-231 cells in which cGAS-STING activation fails to promote type I interferon signaling or ISG induction (Figure 3) .
The mechanisms by which this suppression occurs remain poorly understood. One possibility is through the activation of the p38 MAP-kinase stress pathway, a known inhibitor of interferon signaling downstream of STING ( Figure 5B ). During the late stages of viral infection, p38-mediated phosphorylation of USP21, a deubiquitinating enzyme, negatively regulates STING . The p38 pathway is also thought to be active in chromosomally unstable tumor cells in response to the ongoing stress resulting from chromosome missegregation and endogenous DNA damage (Thompson and Compton, 2010b) . Interestingly, pharmacologic perturbation of p38 selectively influences type I interferon signaling downstream of STING, while other STING-related pathways remain unaffected (Dou et al., 2017) .
A second plausible mechanism for silencing interferon signaling is through modulation of STING signaling strength. The downstream consequences of STING activation are highly dependent on its protein expression levels . For instance, lymphocytes express elevated levels of STING and, as a result, they are exquisitely sensitive to exogenous cGAMP (Cerboni et al., 2017; Gulen et al., 2017) . This cell-type-specific sensitivity is attributed to STING expression level as bone-marrow-derived macrophages and dendritic cells, which are normally activated by cytosolic DNA, exhibit resistance to STING activation. Experimentally increasing STING expression in myeloid-derived cells -to levels comparable to those of T cells -renders the former sensitive to cGAMP. Thus, moderate reductions in STING protein levels or activity might enable some tumor cells to avert the lethal cell-intrinsic consequences of cGAS-STING activation while maintaining a pro-survival program.
A third mechanism of averting cell-intrinsic type I interferon production is through loss of the interferon gene cluster on chromosome 9p ( Figure 5B ). This has been observed in melanoma and acute lymphocytic leukemia, among others (Heyman et al., 1993; Linsley et al., 2014; Litvin et al., 2015) . Tumors with 9p loss exhibit lower basal activity of the interferon pathway and reduced T cell infiltration, providing a mechanism by which locus-specific aneuploidy can enable chromosomally unstable cells to exist in the presence of cytosolic DNA while averting full-fledged immune attack. A survey of >10,000 tumors found in the TCGA database revealed that deep deletions of genes encoded by interferon gene cluster occur in a significant proportion of tumors that have genomically intact copies of the cGAS and STING-coding genes (Figure 4 ).
Beyond Type I Interferon: Alternative CIN-Induced Inflammatory Signaling
While tumor cells might exhibit suppression type I interferon signaling in the presence of cytosolic DNA, STING activation promotes other inflammatory pathways in a tumor-cell-autonomous manner. In contrast to the absence of significant correlation between STING and ISGs, there is a positive correlation between cGAS and STING mRNA levels and those of genes involved in the SASP (Dou et al., 2017) , in line with the previously reported role for the cGAS-STING pathway in cellular senescence (Glü ck et al., 2017; Yang et al., 2017) . STING activates a number of pro-inflammatory transcription factors beyond IRF3, including the canonical and non-canonical NF-kB pathways (Abe and Barber, 2014) . While these factors have overlapping functions, their differential regulation downstream of STING can lead to distinct outcomes. For instance, the canonical NF-kB pathway induces SASP inflammatory factors upon cytosolic DNA signaling in primary IMR90 human lung fibroblasts (Dou et al., 2017; Glü ck et al., 2017) . On the other hand, the noncanonical NF-kB pathway is upregulated upon chronic stimulation of cGAS-STING in MDA-MB-231 cells and plays a critical role in their ability to migrate and spread to distant organs . These pathway-specific functions appear to be independent of the interferon-regulatory factor, IRF3.
The mechanisms regulating inflammation downstream of cGAS-STING in cancer are still poorly characterized. Yet, an important theme that emerges is that of the distinction between acute and chronic inflammation ( Figure 5C ). Unlike acute inflammatory responses, persistent inflammation is known to promote an immune-suppressive pro-metastatic tumor microenvironment (Coussens and Werb, 2002) . Similarly, chronic engagement of the cGAS-STING pathway has pro-tumorigenic effects; TMEM173 knockout mice exhibit reduced carcinogen-induced tumor formation (Ahn et al., 2014) . And while acute STINGmediated SASP represents a barrier against tumorigenesis, chronic SASP-related inflammation is associated with senescence evasion in transformed immortalized IMR90 cells (Dou et al., 2017) . Likewise, chronic cGAS-STING mediate metastatic behavior in MDA-MB-231 breast cancer cells as well as a mesenchymal, treatment-resistant, phenotype in H69M lung cancer tumor models Cañ adas et al., 2018) .
The respective contributions of cell-intrinsic and cell-extrinsic cytosolic DNA signaling during tumor evolution remain to be fully elucidated. It might only require a small subset of tumor cells to experience chromosome missegregation events leading to SASP-related cytokine production in order to recruit immune cells to the tumor microenvironment. An inflamed microenvironment can, in turn, further propagate CIN in tumor cells, either through direct genotoxic stress or induction of EMT, such that this cycle is maintained in a feed-forward fashion (Comaills et al., 2016; Suarez-Carmona et al., 2017) .
Evidence for a CIN-induced immune suppressive phenotype can also be inferred from genomic data of human tumors (Davoli et al., 2017; Taylor et al., 2018; Thorsson et al., 2018) . By carefully annotating the composition of the immune microenvironment, Thorsson et al. found that aneuploidy positively correlates with overall tumor leukocyte fraction in line with activation of inflammatory pathways. However, the composition of the aneuploid tumor microenvironment is dominated by macrophages and is characterized by immune-suppressive phenotypes that comprise the activation of tumor growth-factor-b (TGF-b) (Thorsson et al., 2018). In addition, there are a number of interesting Whereas most tumors retain functional copies of the cGAS and STING coding genes (A), tumor cells have been shown capable of suppressing type I interferon signaling through a variety of mechanisms (B). Chromosome segregation errors can promote chromosome 9p loss, which harbors the interferon gene cluster. Furthermore, they activate the p38 MAP-kinase pathway, which can selectively inhibit ISG induction without affecting other STING-dependent inflammatory signaling, such as the SASP. Therefore, the consequences of cGAS-STING activation in cancer are context dependent (C); acute STING activation in normal cells or near-diploid tumors is likely to exhibit an anti-tumor effect through the activation of type I interferon signaling, cellular senescence, and ensuing T-cell-mediated immunity. As tumors become progressively chromosomally unstable, they adapt to tolerate chronic cGAS-STING signaling in response to cytosolic DNA by downregulating downstream interferon signaling and instead maintaining alternative pathways that promote tumorigenesis, senescence bypass, therapeutic resistance, and metastasis.
correlations between genomic copy-number alterations and tumor-immune composition. For instance, 1p amplification is associated with increased leukocyte infiltration, whereas loss of 19q, which harbors TGFB1, reduces the tumor leukocyte fraction. Furthermore, amplifications of chromosome 2, 20q, 22q, as well as deletions of 5q, 9p, and chr19 are associated with changes in macrophage polarity (Thorsson et al., 2018) . These interesting associations highlight the need to develop mouse models that enable the dissection of the bidirectional crosstalk between tumor karyotypes and the immune microenvironment.
The versatility of CIN-induced inflammation and cGAS-STING signaling in cancer cells demonstrates that tumor cells can alter their circuitry downstream of STING in a context-dependent manner to minimize the lethal consequences of cell-autonomous interferon signaling while permitting alternative inflammatory pathways that sustain tumor growth, therapeutic resistance, and metastasis. Furthermore, the distinction between acute and chronic activation states of cytosolic dsDNA sensing are critical to interpreting experimental results as well as data derived from clinical tumor samples.
Aneuploidy as a Vehicle for Immune Evasion
Another means by which karyotypic abnormalities can directly promote immune evasion is through direct interference with antigen presentation. Copy-number loss of heterozygosity in the human-leukocyte antigen (LOHHLA) locus occurs in nearly 40% of non-small cell lung cancers (NSCLC) . Interestingly, LOHHLA is associated with a high subclonal neoantigen burden as well as APOBEC-mediated mutagenesis. These tumors also exhibit increased T-cell infiltration, suggesting strong selection for aneuploid clones that finetune their MHC-class I dosage. Similar observations have been noted by Chowell et al. in melanoma, whereby somatic LOH at the HLA locus is associated with poor prognosis and a worse response to immune checkpoint blockade (Chowell et al., 2018) . Along the same vein, multi-region sequencing in highgrade serous ovarian cancer reveals similar LOH in tumor regions that are most replete with CD8 T cells, presenting evidence for dynamic spatial selection .
CIN as a Driver of Metastasis
The role of CIN in metastasis has long been suspected, given the emergence of karyotypic complexity during the later stages of tumor progression. The ability to genetically engineer cancer cells with varying rates of chromosome missegregation has enabled the decoupling of the inflammatory consequences of CIN from that of aneuploidy: by comparing chromosomally unstable tumor cells to their chromosomally stable-yet still aneuploid-counterparts . In human breast and lung cancer-derived cells, chronic cGAS-STING activity resulting from chromosome segregation errors has been shown to promote migration, invasion, and metastasis. These phenotypes are mediated by the noncanonical NF-kB pathway downstream of STING (Figure 3) . Suppression of CIN, depletion of STING, or the noncanonical NF-kB transcription factors reduce metastasis in chromosomally unstable tumor cells.
The ability of tumor cells to co-opt the noncanonical NF-kB pathway provides insight into the mechanism of CIN-driven cancer metastasis. This pathway is a developmental program involved in monocyte and lymphocyte maturation, and its activation follows relatively slow kinetics (Sun, 2011; Vogel et al., 2013) , making it an ideal candidate to respond to the ongoing presence of cytosolic DNA ( Figure 5 ). Interestingly, parallels to this scenario are observed during normal inflammation and raise the intriguing possibility that tumor cells engage in some form of immune mimicry as they respond to chronic activation of cytosolic DNA signaling. First, cells from the myeloid lineage are activated in response to cytosolic DNA-originating from tumor cells or from viral infections-leading to increased migratory behavior Kis-Toth et al., 2011) . Second, polyploidy is coincident with macrophage activation in granulomas, suggesting a potential role for cytosolic DNA in this process. Third, transient nuclear rupture during leukocytes migration and extravasation leads to cGAS-STING activation (Denais et al., 2016; Herrtwich et al., 2016) . It is, therefore, tempting to postulate that cytosolic DNA signaling is an evolutionary conserved cue for physiologic migratory behavior during inflammation that is co-opted by tumor cells to spread to distant organs.
In addition to inflammatory signaling, aneuploidy can cooperate with chromosome missegregation or even independently facilitate metastatic progression through gene dosage alteration (Campbell et al., 2010; Notta et al., 2016) . Using KRAS-driven human cancer cells as well as genetically engineered murine pancreatic tumors, Muller et al. demonstrated that increased mutant-KRAS gene dosage led to pancreatic cancer metastasis, whereby cells with the highest number of copies exhibited aggressive undifferentiated phenotypes (Mueller et al., 2018) . In other settings, prospective multi-region sequencing of human renal cell carcinoma (RCC) revealed a significant increase in copy-number heterogeneity in metastatic samples with recurrent losses of chromosomes 9p and 14q (Turajlic et al., 2018) . This raises the prospects that 9p loss promotes tolerance for cGAS-STING signaling arising from chromosome missegregation that accompanies the transition from primary tumors to metastases in RCC. This work highlights the need to generate genetically engineered mouse models that can better probe the relationship between CIN and metastasis in immune-competent environments.
CIN and Therapeutic Response and Resistance
It has long been appreciated that CIN facilitates treatment resistance by generating heterogeneity at the level of gene dosage. Yet, to maintain equipoise between genomic chaos and the acquisition of heterogeneity, cancer cells must restrict chromosome missegregation rates within a limited range that maximizes their viability (Burkard and Weaver, 2017; Laughney et al., 2015) . This notion underlies, in part, the anti-neoplastic effects of therapies that promote CIN. For instance, widely used agents such as taxol, PARP inhibitors, and ionizing radiation are among the strongest inducers of chromosome segregation errors Lee et al., 2016) . In addition to their well-characterized cellular mechanisms of action, their effect on chromosome segregation invokes a contribution of the cGAS-STING pathway leading to anti-tumor immunity. To this end, Zierhut et al. have demonstrated that STING is an important determinant of mitotic cell death when breast cancer cell lines are treated with taxol in vitro (Zierhut and Funabiki, 2017) .
Similarly, recent reports link tumor response to PARP inhibitors to their ability to engage cGAS-STING signaling as well as antitumor immunity in murine transplantable ovarian and colorectal cancer models (Shen, 2018) . In addition to their action on replication forks, PARP inhibitors perturb mitotic chromosome segregation, providing a direct link for the generation of cytosolic dsDNA (Schoonen et al., 2017) . Finally, cytosolic DNA signaling in tumor cells can promote systemic anti-tumor immunity after radiation treatment where regression of transplantable breast and melanoma tumors occurs in a T-cell-dependent manner (Harding et al., 2017; Vanpouille-Box et al., 2017) .
By the same token, sustained cGAS-STING activation can engender therapeutic resistance. Host STING-induced chronic type I interferon signaling during prolonged exposure to fractionated radiation therapy promotes tumor radio-resistance in transplanted MC38 colon tumors. This treatment resistance is mediated by the mobilization of myeloid-derived suppressor cells (Liang et al., 2017) . In another study, chronic interferon exposure has been shown to promote the derepression and transcription of anti-sense endogenous retrovirus-coding sequences at the STAT1 and EZH2 promoters. The resulting double-stranded RNA, as well as dsDNA produced through reverse-transcription, sustain MAVS and cGAS-STING signaling and promote mesenchymal cell traits, treatment resistance, and an immunesuppressive microenvironment (Cañ adas et al., 2018) . These findings have important implications on therapeutic design and lead us to question the role of long-term use of cytotoxic therapies in intact or large residual tumors. Indeed, lingering viable tumor cells can acquire migratory and mesenchymal phenotypes after prolonged neoadjuvant treatment with cytotoxic therapies, which, in some pre-clinical breast cancer models, are associated with increased metastasis to the liver (Karagiannis et al., 2017; Li et al., 2016) . It is tempting to postulate that these effects are secondary to chronic inflammatory stimulation, such that, if the therapy is unsuccessful in eliminating all tumor cells, the residual disease acquires an inducible aggressive phenotype.
Concluding Remarks: CIN as a Therapeutic Vulnerability
The importance of CIN in tumor evolution is becoming increasingly appreciated, and an understanding of the dual role of CIN Figure 6 . An Integrated Approach to Exploit CIN for a Therapeutic Benefit A viable adoption of CIN-directed therapies in the clinic must integrate a multi-disciplinary approach as well as careful patient selection. The widespread prevalence of CIN in advanced tumors offers an opportunity to devise therapeutic strategies that aim to target multi-drug resistance and metastatic progression. Furthermore, a better understanding of the mechanisms of CIN-induced inflammation might enable the development of novel approaches to augment anti-tumor immunity and synergize with existing immunotherapeutic agents used in the context of advanced metastatic disease.
as an activator of innate immune signaling as well as a vehicle for tumor adaptation is critical to our ability to target it for a therapeutic benefit. Despite recent advances in our understanding of CIN in biological systems, clinical adoption of CIN-directed therapies remains at its infancy and there are currently no drugs in the clinic that can be used to suppress chromosome segregation errors. Successful clinical implementation will hinge on interdisciplinary integration of cell biology, computational modeling, single-cell analyses, and genetically engineered mouse models, guided by the use of human tumor samples ( Figure 6 ). Careful patient selection will undoubtedly be central to our ability to determine when it is beneficial to modulate CIN and when its effects might be deleterious, as is the case with chronic inflammation. Furthermore, identifying means to prevent tumor cell adaptation to cytosolic DNA will be key to our ability to target an otherwise lethal feature of cancer for a therapeutic benefit ( Figure 6 ). Given the widespread nature of CIN in human cancer, CIN-directed therapies have the potential to profoundly impact clinical outcomes, including minimizing the onset of therapeutic resistance, treating advanced and metastatic disease, and augmenting systemic anti-tumor immunity.
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